Clinical Radioimmunotherapy and Systemic Targeted Radiopharmaceutical Therapy (STaRT) programs in a radiation oncology environment

Am J Clin Oncol. 2006 Dec;29(6):543-7. doi: 10.1097/01.coc.0000248941.97523.b2.
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Hematology / organization & administration
  • Hematology / trends
  • Humans
  • Interprofessional Relations
  • Lymphoma, B-Cell / immunology
  • Lymphoma, B-Cell / radiotherapy
  • Nuclear Medicine / organization & administration
  • Nuclear Medicine / trends
  • Patient Care Team
  • Radiation Oncology / organization & administration
  • Radiation Oncology / trends*
  • Radioimmunotherapy / trends*
  • Radiopharmaceuticals / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Radiopharmaceuticals
  • ibritumomab tiuxetan
  • tositumomab I-131